AI & Electronic Signatures in Regulated Industries: Compliance Guide

Artificial intelligence is entering every corner of the life sciences, from drug discovery and clinical trial design to manufacturing quality control and post-market surveillance. At the same time, e-signature workflows remain the backbone of regulatory compliance, governing how organizations approve batch records, sign off on clinical documents, and release products. The convergence of these two forces is creating both extraordinary opportunity and new compliance questions that QA managers, IT leaders, and regulatory affairs professionals need to answer now, before regulators answer for them.

This article maps the fast-moving regulatory environment for AI in regulated industries, explains where AI intersects with electronic signature workflows, and provides a practical framework for adopting AI-enhanced compliance tools without running afoul of FDA 21 CFR Part 11, EU GMP Annex 11, or the EU AI Act.

The Convergence of AI and Electronic Signatures in Life Sciences

Life sciences organizations have spent the last two decades digitizing their quality and compliance operations. Paper logbooks gave way to electronic records. Wet-ink signatures were replaced by electronic ones. Audit trails became computer-generated and cryptographically secured. Regulations like 21 CFR Part 11 and EU GMP Annex 11 established the rules for trustworthy electronic records, and most organizations have now made that transition.

Now a second wave is underway. AI and machine learning models are being embedded into quality management systems, document management platforms, regulatory submission tools, and manufacturing execution systems. These models can analyze patterns in data, predict compliance risks, automate routine decisions, and flag anomalies that human reviewers might miss.

But unlike the first digital transformation, which swapped paper for pixels while keeping the same human decision-making processes, AI introduces a fundamentally different question: when an algorithm assists or makes a decision, who is accountable? That question sits at the heart of the regulatory frameworks now taking shape on both sides of the Atlantic.

FDA's AI/ML Guidance Landscape

January 2025: AI-Enabled Device Software Functions Draft Guidance

On January 7, 2025, the FDA published a landmark draft guidance: Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations. This document is the FDA's most thorough articulation of how it expects AI-enabled products to be developed, documented, submitted, and monitored throughout their total product lifecycle (TPLC).

The draft guidance applies to software functions that meet the statutory definition of a device under Section 201(h) of the FD&C Act and are "AI-enabled device software functions" (AI-DSFs), meaning they implement one or more AI models. Key submission requirements include:

• Model description: Architecture, feature descriptions, selection processes, loss functions, parameters, and pre/post-processing methods.
• Data management: Data lineage, splits, quality control criteria, and augmentation or synthesis methods used during training.
• Performance evaluation: Validation results tied directly to intended-use claims, including subgroup analysis across demographic groups.
• Bias analysis and mitigation: Evidence that the device benefits all relevant demographic groups (race, ethnicity, sex, age) similarly.
• Human-AI workflow: Documentation of how human users interact with the AI's outputs, including override capabilities.
• Predetermined Change Control Plans (PCCPs): If post-market updates are planned, a PCCP describing anticipated modifications and the methodology for implementing them in a controlled manner.

The transparency and explainability requirements are particularly significant for regulated industries. The FDA explicitly requests detailed information about the technical characteristics of the model, the algorithms used, and the methods for generating outputs. That's a clear signal that "black box" AI won't pass regulatory scrutiny.

Good Machine Learning Practice (GMLP)

In January 2025, the International Medical Device Regulators Forum (IMDRF) finalized its technical document on Good Machine Learning Practice (GMLP), 10 guiding principles for the development of safe, effective, and high-quality AI/ML-enabled medical devices. The IMDRF principles align with those previously identified jointly by the FDA, Health Canada, and the UK's MHRA, giving them multinational regulatory backing.

GMLP principles cover the entire AI lifecycle: from data quality and representativeness through model development, testing, deployment, and ongoing monitoring. Principle 10 specifically emphasizes the importance of monitoring deployed models for performance and managing the risks associated with retraining, which is directly relevant to any AI component embedded in an e-signature or quality management workflow.

January 2026: FDA-EMA Joint Guiding Principles

On January 14, 2026, the FDA and European Medicines Agency (EMA) jointly released Guiding Principles of Good AI Practice in Drug Development, 10 high-level principles for the responsible use of AI across the entire medicines lifecycle. This marks the first transatlantic regulatory alignment on AI in drug development, spanning early research, clinical trials, manufacturing, and post-market safety surveillance.

Key themes include human-centric design, alignment with ethical values, a risk-based approach, strong data governance, multidisciplinary expertise, lifecycle management, and clear communication about AI systems. While adoption is currently voluntary, the principles signal the direction of future binding guidance on both sides of the Atlantic. Organizations that align early will have a head start.

EU AI Act: What It Means for Regulated Software

The EU AI Act (Regulation 2024/1689) entered into force on August 1, 2024, making it the world's first full legal framework for artificial intelligence. Its phased implementation timeline is worth tracking:

• February 2, 2025: Prohibited AI practices and AI literacy obligations took effect.
• August 2, 2025: Governance rules and obligations for general-purpose AI models became applicable.
• August 2, 2026: Full application, including high-risk AI system obligations.
• August 2, 2027: Extended transition for high-risk AI systems embedded in regulated products (including medical devices under MDR/IVDR).

High-Risk Classification for Life Sciences

The EU AI Act classifies AI systems into four risk tiers: unacceptable, high, limited, and minimal. For life sciences, the high-risk category matters most. AI systems used as safety components of medical devices or that are medical devices themselves, and that require third-party conformity assessment by a notified body, are classified as high-risk. In practice, this means AI embedded in MDR Class IIa, IIb, and III devices and IVDR Class B, C, and D devices will typically qualify.

High-risk classification triggers extensive obligations: technical documentation, risk management systems, data governance, transparency, human oversight, accuracy and robustness requirements, conformity assessment, post-market surveillance, and incident reporting. Medical device manufacturers face a dual regulatory framework, as the AI Act applies in parallel to the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

Where AI Meets E-Signatures: Five Use Cases

While the regulatory frameworks above focus on AI-enabled medical devices and drug development, the implications extend to every software system used in regulated operations, including e-signature platforms. Here are five areas where AI is already enhancing or will soon enhance electronic signature workflows:

1. AI-Assisted Document Routing and Workflow Automation

Traditional e-signature workflows rely on predefined routing rules: a document goes to Signer A, then Signer B, then Approver C. AI can analyze document content, metadata, and organizational context to recommend or dynamically adjust routing. For example, an AI model could identify that a deviation report requires an additional quality unit review based on the nature of the deviation, or that a batch record amendment should be escalated based on the product's risk category.

The compliance implication: any AI-assisted routing must be validated, and the logic behind routing recommendations must be documented in the audit trail. If the system recommends skipping or adding a signer, the reason must be traceable.

2. Intelligent Field Extraction and Auto-Population

AI-powered optical character recognition (OCR) and natural language processing (NLP) can extract data from source documents and auto-populate signature request fields: names, titles, dates, document references. This reduces manual data entry errors and accelerates workflows. But under 21 CFR Part 11, each signer must verify that the information attributed to them is accurate. Auto-populated fields must be clearly identified as system-generated and require explicit confirmation before signing.

3. AI-Powered Identity Verification

Biometric verification (facial recognition, voice matching) and behavioral analytics (keystroke dynamics, device fingerprinting) can strengthen signer identity assurance beyond traditional username-password and TOTP-based two-factor authentication. The FDA has long recognized biometric signatures under 21 CFR Part 11 Subpart C, Section 11.200. AI enhances these mechanisms by learning and adapting to individual behavioral patterns, flagging anomalous authentication attempts that might indicate credential compromise.

4. Anomaly Detection in Audit Trails

A compliant audit trail captures every action on an electronic record. But generating data and reviewing it are different challenges. AI-powered anomaly detection can analyze audit trail patterns and flag unusual activity: signatures applied outside business hours, bulk approvals in rapid succession, a signer approving documents outside their usual scope, or sequential patterns that suggest rubber-stamping rather than genuine review. This type of monitoring directly supports the ALCOA+ principles of completeness and accuracy.

5. Predictive Compliance Monitoring

Rather than discovering compliance gaps during an inspection or internal audit, AI models can predict them. By analyzing historical data (training completion rates, signature turnaround times, deviation frequencies, CAPA closure rates), predictive models can identify organizational units, processes, or document types that are trending toward non-compliance. This shifts the compliance posture from reactive to proactive, giving QA teams time to intervene before a gap becomes a finding.

Part 11 Considerations for AI-Enhanced Systems

Embedding AI into systems governed by 21 CFR Part 11 doesn't create new regulatory obligations. It creates new dimensions within existing ones. These Part 11 requirements take on special significance in AI-enhanced environments:

• System validation (11.10(a)): AI models must be validated for their intended use. This includes validating not just the model's accuracy at deployment but its ongoing performance over time, especially if the model learns or adapts. GAMP 5 Category 5 (custom software) principles and the FDA's Computer Software Assurance (CSA) framework both apply.
• Audit trails (11.10(e)): Every AI-assisted action must be recorded in the audit trail, including the model's recommendation, the confidence score (if applicable), and the human decision that followed. The audit trail must make it possible to reconstruct whether a human accepted, modified, or overrode an AI recommendation.
• Authority checks (11.10(g)): AI can't expand a user's authority. If a model recommends that a document be routed to a user who lacks signing authority for that document type, the system must enforce the authority restriction regardless of the AI's recommendation.
• Operational system checks (11.10(f)): Systems must enforce permitted sequencing of steps. AI-driven workflow optimizations must not bypass required review sequences or approval gates defined by SOPs and predicate rules.
• Record integrity (11.10(c)): AI-generated or AI-modified data within electronic records must be protected from unauthorized alteration, and the system must detect invalid or altered records.

The Human-in-the-Loop Requirement

The single most important principle at the intersection of AI and electronic signatures in regulated industries is this: AI cannot replace human judgment in the act of signing. An electronic signature under 21 CFR Part 11 is "the legally binding equivalent of the individual's handwritten signature" (Section 11.3(b)(7)). It is an act of individual accountability: the signer attests that they've reviewed the record, that the information is accurate, and that they accept responsibility for its content.

No AI model can assume that accountability. An algorithm can recommend approval, highlight risks, pre-populate fields, and verify identity, but the act of signing (the conscious, deliberate assertion of "I reviewed this, and I am responsible") must remain with a human being. This isn't a technical limitation; it's a legal and ethical requirement embedded in the regulation's purpose.

The FDA-EMA joint principles reinforce this position: AI should be human-centric by design, and the human role in decision-making must be clearly defined. The EU AI Act similarly mandates human oversight for high-risk AI systems, requiring that humans can understand the AI system's capabilities and limitations, properly monitor its operation, and intervene or override when necessary.

In practice, this means:

• AI can present a signing recommendation, but the signer must independently confirm their intent.
• AI-generated summaries or risk assessments presented to signers must be clearly labeled as AI-generated.
• The signer's identity must be verified through established mechanisms (password + TOTP 2FA), not delegated to an AI system alone.
• Audit trails must distinguish between actions taken by the AI and actions taken by the human signer.

Traditional vs. AI-Enhanced E-Signature Workflows

This table compares traditional e-signature workflows with AI-enhanced approaches across key compliance dimensions:

Preparing Your Organization for AI in Compliance

Adopting AI-enhanced compliance tools isn't just a technology project; it's a quality system evolution. Organizations that approach it methodically will gain efficiency and reduce compliance risk. Those that adopt AI tools without governance will create new audit findings. Here's a practical framework:

1. Conduct an AI readiness assessment. Inventory all current GxP systems and identify where AI capabilities are already embedded (many modern QMS and EDMS platforms now include AI features). Map each AI function to its Part 11 and GxP compliance requirements.
2. Establish an AI governance framework. Define who approves the deployment of AI tools in GxP processes, what validation activities are required, and how ongoing performance monitoring will be conducted. Align the framework with the FDA-EMA guiding principles and your existing quality management system.
3. Update validation protocols. Standard IQ/OQ/PQ protocols must be extended to cover AI-specific concerns: model performance benchmarks, data quality requirements, bias testing, drift monitoring thresholds, and explainability verification. The FDA's CSA guidance supports risk-based approaches that can keep validation proportionate.
4. Define human-in-the-loop requirements by use case. Not all AI applications carry the same risk. A model that suggests document routing is lower risk than a model that evaluates data integrity. Map each use case to a risk level and define the corresponding level of human oversight, from batch review for low-risk applications to individual decision confirmation for high-risk ones.
5. Train your workforce. The EU AI Act specifically includes an AI literacy obligation (effective February 2025). Beyond regulatory requirements, your teams need to understand what AI tools are doing, what their limitations are, and when to override or question their recommendations. Training must be documented per GxP requirements.
6. Audit trail everything. Make sure all AI-assisted actions, recommendations, and human responses are captured in your audit trail. This is both a Part 11 requirement and a practical necessity for demonstrating compliance during inspections.
7. Monitor regulatory developments. The regulatory environment for AI in life sciences is evolving fast. The FDA's January 2025 draft guidance will likely be finalized in 2026. The EU AI Act's high-risk obligations take full effect in August 2026. More guidance from the FDA, EMA, and IMDRF is expected. Assign regulatory intelligence responsibilities to make sure your organization stays current.

The Bottom Line

AI will transform how regulated industries manage compliance, quality, and documentation. That transformation is already underway. The FDA's January 2025 draft guidance on AI-enabled device software functions, the IMDRF's finalized GMLP principles, the January 2026 FDA-EMA joint guiding principles, and the EU AI Act collectively establish a regulatory framework that is demanding but workable.

For e-signature workflows specifically, the message from regulators is consistent: AI can assist, recommend, verify, and monitor, but it can't sign. The human-in-the-loop isn't a transitional requirement that will fade as AI matures. It's a fundamental principle rooted in individual accountability, legal liability, and the regulatory purpose of electronic signatures themselves.

Organizations that embrace AI responsibly, with proper validation, governance, explainability, and human oversight, will see real benefits: faster document turnaround, earlier detection of compliance risks, stronger audit trail monitoring, and reduced manual burden on quality teams. Those that adopt AI tools without these safeguards will trade one set of compliance risks for another.

The path forward is clear: build on a compliant foundation, govern AI adoption rigorously, keep humans accountable for signing decisions, and audit trail every AI-assisted action. The regulations aren't trying to slow down AI adoption. They're trying to ensure it's done in a way that protects patients, data integrity, and public trust.

For a full understanding of the regulatory foundation that underpins AI compliance in life sciences, explore our guides on FDA 21 CFR Part 11, ALCOA+ data integrity principles, and GxP compliance for electronic records.